The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.90
Bid: 1.80
Ask: 2.00
Change: 0.375 (24.59%)
Spread: 0.20 (11.111%)
Open: 1.525
High: 1.90
Low: 1.90
Prev. Close: 1.525
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

1 Jun 2023 11:00

RNS Number : 3512B
Shield Therapeutics PLC
01 June 2023
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

Shield Therapeutics plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

x

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

x

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

Nutrition-Wellness Venture SA

City and country of registered office (if applicable)

Vevey, Switzerland

4. Full name of shareholder(s) (if different from 3.) v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached vi:

16 March 2023 and 9 May 2023 (post AOP conversion)

6. Date on which issuer notified (DD/MM/YYYY):

25 May 2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

7.85%

0%

7.85%

56,008,541

Position of previous notification (if

applicable)

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BYV81293

56,008,541

0

7.85%

0%

SUBTOTAL 8. A

56,008,541

7.85%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

X

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Nestle S.A.

7.85%

7.85%

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information xvi

 

Place of completion

Vevey, Switzerland

Date of completion

31 May 2023

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFBMLTMTIMMPJ
Date   Source Headline
17th Feb 20229:00 amRNSPrice Monitoring Extension
17th Feb 20227:00 amRNSFull Year Trading Update
4th Feb 20227:00 amRNSKOL Investor Event on Iron Deficiency
7th Jan 20227:00 amRNSInvestor Presentation
5th Jan 20227:00 amRNSLicence Agreement in Canada for Accrufer®
30th Dec 20219:06 amRNSSecond Price Monitoring Extn
30th Dec 20219:00 amRNSPrice Monitoring Extension
29th Dec 202111:05 amRNSSecond Price Monitoring Extn
29th Dec 202111:00 amRNSPrice Monitoring Extension
16th Dec 202111:05 amRNSSecond Price Monitoring Extn
16th Dec 202111:00 amRNSPrice Monitoring Extension
16th Dec 20217:00 amRNSPatient Access Expands for Accrufer®
7th Oct 20219:45 amEQSHardman & Co Research: Shield Therapeutics (STX) Life Sciences Investor Forum research
30th Sep 20215:30 pmRNSBlock Listing 6 Monthly Return
27th Sep 20217:00 amRNSJose A. Menoyo Appointed as Chief Medical Officer
21st Sep 20217:00 amRNSInvestor presentation
23rd Aug 20217:00 amRNSPDMR Transaction Notification
20th Aug 202111:08 amEQSHardman & Co Research: Shield Therapeutics (STX) - Focused on US market penetration
17th Aug 20217:00 amRNSHalf-year Report
12th Aug 20217:25 amEQSHardman & Co Video Event | Shield Therapeutics plc - Investor Forum
12th Aug 20217:00 amRNSLicence agreement secured in Republic of Korea
11th Aug 20217:00 amRNSNotice of Results
9th Aug 20217:00 amRNSAEGIS-CKD study results published in AJKD
4th Aug 20214:41 pmRNSSecond Price Monitoring Extn
4th Aug 20214:35 pmRNSPrice Monitoring Extension
4th Aug 20212:05 pmRNSSecond Price Monitoring Extn
4th Aug 20212:00 pmRNSPrice Monitoring Extension
24th Jun 20217:00 amRNSUS launch of Accrufer® confirmed for July 1, 2021
23rd Jun 20214:40 pmRNSSecond Price Monitoring Extn
23rd Jun 20214:35 pmRNSPrice Monitoring Extension
21st Jun 20211:35 pmRNSInvestor presentation
18th Jun 20217:00 amRNSDirectorate Change
17th Jun 20212:30 pmRNSResults of 2021 Annual General Meeting
15th Jun 20216:15 pmRNSGrant of share options to the CEO
28th May 20217:00 amRNSAppointment of new Chief Executive Officer
28th May 20217:00 amRNSTotal Voting Rights
26th May 202110:35 amEQSHardman & Co Research: Shield Therapeutics (STX): Accrufer launch on schedule
21st May 20217:00 amRNSUS update
18th May 20217:00 amRNSAEGIS-H2H study results published in IBD
17th May 20217:00 amRNSCommencement of trading on the OTCQX Best Market
13th May 20213:00 pmRNS2020 Annual Report and 2021 AGM Notice
10th May 20217:00 amRNSAppointment of Two Non-Executive Directors
6th May 20211:44 pmRNSTotal Voting Rights Update
29th Apr 20217:00 amRNSPreliminary Results
22nd Apr 20217:00 amRNSNotice of Results
7th Apr 20219:33 amRNSHolding(s) in Company
7th Apr 20219:31 amRNSHolding(s) in Company
6th Apr 202111:05 amRNSSecond Price Monitoring Extn
6th Apr 202111:00 amRNSPrice Monitoring Extension
6th Apr 20217:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.